CoChat
Sign Up
Cited by 118Neuropeptides and Animal PhysiologyAlzheimer's disease research and treatmentsNeuroscience and Neuropharmacology Research

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

μ-, δ- and κ-opioid receptor populations are differentially altered in distinct areas of postmortem brains of Alzheimer’s disease patients

Mathieu-Kia, Anne-Marie, Fan, Li-Qun, Kreek, Mary Jeanne, Simon, Eric J., Hiller, Jacob M.·2001·Brain Research
DOI 10.1016/s0006-8993(00)03302-3
Open this paper in CoChat — free account

Abstract

The putative role of the opioid system in cognitive and memory functions prompted us to search for possible changes in the cohort of the major opioid receptors, mu, delta and kappa, in Alzheimer's disease. The present study examines alterations in opioid receptor levels by quantitative autoradiography. These experiments were carried out on coronal sections of postmortem brains from Alzheimer's disease patients and from aged-matched, dementia-free individuals. Brain sections were labeled with the tritiated forms of mu-, delta- and kappa-opioid ligands; DAMGO ([D-Ala(2),N-Me-Phe(4),Gly-ol(5)]-enkephalin), DPDPE ([D-Pen2,5]-enkephalin) and bremazocine (in the presence of mu- and delta-ligands), respectively. Nonspecific binding was determined in the presence of naloxone (10 microM). Brain areas analyzed were caudate, putamen, amygdaloid complex, hippocampal formation and various cerebral and cerebellar cortices. Image analyses of autoradiographs show, that in comparison to the same areas in control brain, statistically significant reductions in mu-opioid receptor binding occur in the subiculum and hippocampus of Alzheimer's disease brains. Binding of delta-opioid receptors is also decreased in the amygdaloid complex and ventral putamen of Alzheimer's disease brains. In contrast, large increases of kappa-opioid receptor binding are found in the dorsal and ventral putamen as well as in the cerebellar cortex of Alzheimer's disease brains. Levels of mu- delta- and kappa-opioid recep…

Overview

Integrity signals

Registry

Crossref · 10.1016/s0006-8993(00)03302-3

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 61

  1. Barg, 1993, Opioid receptor density changes in Alzheimer amygdala and putamen, Brain Res., 632, 209, 10.1016/0006-8993(93)91155-L · DOI
  2. Bierer, 1995, Neurochemical correlates of dementia severity in Alzheimer’s disease: relative importance of the cholinergic deficits, J. Neurochem., 64, 749, 10.1046/j.1471-4159.1995.64020749.x · DOI
  3. Blackburn, 1988, Autoradiographic localization of δ opiate receptors in rat and human brain, Neuroscience, 27, 497, 10.1016/0306-4522(88)90283-7 · DOI
  4. Boissiere, 1997, Choline acetyltransferase mRNA expression in the striatal neurons of patients with Alzheimer’s disease, Neurosci. Lett., 225, 169, 10.1016/S0304-3940(97)00210-3 · DOI
  5. Braak, 1996, Pattern of brain destruction in Parkinson’s and Alzheimer’s diseases, J. Neural Transm., 103, 455, 10.1007/BF01276421 · DOI
  6. Cohen, 1997, Opiate receptor avidity and cerebral blood flow in Alzheimer’s disease, J. Neurol. Sci., 148, 171, 10.1016/S0022-510X(96)05315-4 · DOI
  7. Cross, 1986, The selectivity of the reduction of serotonin S2 receptors in Alzheimer-type dementia, Neurobiol. Aging, 7, 3, 10.1016/0197-4580(86)90019-9 · DOI
  8. Delay-Goyet, 1987, Regional distribution of μ, δ and κ opioid receptors in human brains from controls and Parkinsonian subjects, Brain Res., 414, 8, 10.1016/0006-8993(87)91321-7 · DOI
  9. Gabilondo, 1994, μ-Opioid receptor and α2-adrenoceptor agonist binding sites in the postmortem brain of heroin addicts, Psychopharmacology (Berl.), 115, 135, 10.1007/BF02244763 · DOI
  10. Gabilondo, 1995, Increased density of μ-opioid receptors in the postmortem brain of suicide victims, Brain Res., 682, 245, 10.1016/0006-8993(95)00333-L · DOI · Paper page
  11. Garcia-Sevilla, 1997, Regulation of immunolabelled μ-opioid receptors and protein kinase C- α and ζ isoforms in the frontal cortex of human opiate addicts, Neurosci. Lett., 226, 29, 10.1016/S0304-3940(97)00227-9 · DOI
  12. Garlind, 1995, Preservation of κ 1 opioid receptor recognition site density and regulation by G-proteins in the temporal cortex of patients with Alzheimer’s disease, Neurosci. Lett., 185, 131, 10.1016/0304-3940(94)11243-C · DOI
  13. Gross-Isseroff, 1990, Regionally selective increases in μ opioid receptor density in the brains of suicide victims, Brain Res., 530, 312, 10.1016/0006-8993(90)91301-V · DOI
  14. Henderson, 1989, Multicenter trial of naloxone in Alzheimer’s disease, Ann. Neurol., 25, 404, 10.1002/ana.410250413 · DOI
  15. Hiller, 1987, Selective changes in μ, δ and κ opioid receptor binding in certain limbic regions of the brain in Alzheimer’s disease patients, Brain Res., 406, 17, 10.1016/0006-8993(87)90764-5 · DOI
  16. Hiller, 1996, Laminar distribution of the multiple opioid receptors in the human cerebral cortex, Neurochem. Res., 21, 1333, 10.1007/BF02532374 · DOI
  17. Hiramatsu, 1997, Effects of dynorphin A (1-13) on carbon monoxide-induced delayed amnesia in mice, Pharmacol. Biochem. Behav., 56, 73, 10.1016/S0091-3057(96)00159-1 · DOI
  18. Hiramatsu, 1998, Reversion of muscarinic autoreceptor agonist-induced acetylcholine decrease and learning impairment by dynorphin A (1-13), an endogenous κ-opioid receptor agonist, Br. J. Pharmacol., 123, 920, 10.1038/sj.bjp.0701671 · DOI
  19. Hiramatsu, 1998, Effects of U-50,488H on scopolamine-, mecamylamine- and dizocilpine-induced learning and memory impairment in rats, J. Pharmacol. Exp. Ther., 284, 858
  20. Hyman, 1997, Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease, J. Neuropathol. Exp. Neurol., 56, 1095, 10.1097/00005072-199710000-00002 · DOI · Paper page
  21. Ikeda, 1993, Differential alterations in adenosine A1 and κ 1 opioid receptors in the striatum in Alzheimer’s disease, Brain Res., 616, 211, 10.1016/0006-8993(93)90211-5 · DOI
  22. Ilyutchenok, 1995, Memory retrieval enhancement by κ opioid agonist and μ, δ antagonists, Pharmacol. Biochem. Behav., 52, 683, 10.1016/0091-3057(95)00099-I · DOI
  23. Itoh, 1993, Dynorphin A-(1-13) potently prevents memory dysfunctions induced by transient cerebral ischemia in mice, Eur. J. Pharmacol., 234, 9, 10.1016/0014-2999(93)90699-I · DOI
  24. Itoh, 1994, Dynorphin A-(1-13) potently improves the impairment of spontaneous alternation performance induced by the μ-selective opioid receptor agonist DAMGO in mice, J. Pharmacol. Exp. Ther., 269, 15
  25. Jansen, 1990, Alzheimer’s disease: changes in hippocampal N-methyl-d-aspartate, quisqualate, neurotensin, adenosine, benzodiazepine, serotonin and opioid receptors – an autoradiographic study, Neuroscience, 39, 613, 10.1016/0306-4522(90)90246-Z · DOI
  26. Jenni-Eiermann, 1984, Studies on neurotransmitter binding in senile dementia. Comparison of Alzheimer’s and mixed vascular-Alzheimer’s dementias, Gerontology, 30, 350, 10.1159/000212656 · DOI
  27. Jorm, 1987, The prevalence of dementia: a quantitative integration of the literature, Acta Psychiatr. Scand., 76, 465, 10.1111/j.1600-0447.1987.tb02906.x · DOI
  28. Kreek, 1978, Medical complications in methadone patients, Ann. NY Acad. Sci., 311, 110, 10.1111/j.1749-6632.1978.tb16769.x · DOI
  29. Lehericy, 1989, Selective loss of cholinergic neurons in the ventral striatum of patients with Alzheimer disease, Proc. Natl. Acad. Sci. USA, 86, 8580, 10.1073/pnas.86.21.8580 · DOI
  30. Mackay, 1994, κ-1 opioid receptors of the temporal cortex are preserved in Alzheimer’s disease, J. Neural Transm. Park. Dis. Dement. Sect., 7, 73, 10.1007/BF02252664 · DOI
  31. Madar, 1996, Imaging of δ opioid receptors in human brain by N1′-([11C]methyl)naltrindole and PET, Synapse, 24, 19, 10.1002/(SICI)1098-2396(199609)24:1<19::AID-SYN3>3.0.CO;2-J · DOI
  32. Maurer, 1983, Multiple opiate receptor in human brain: an autoradiographic investigation, Life Sci., 33, 231, 10.1016/0024-3205(83)90485-X · DOI
  33. Minami, 1995, Molecular biology of the opioid receptors: structures, functions and distributions, Neurosci. Res., 23, 121, 10.1016/0168-0102(95)00933-K · DOI
  34. Mueller-Gaertner, 1991, μ-Opiate receptor binding in amygdala in Alzheimer’s disease: in vivo quantification by 11C carfentanil and PET, J. Cereb. Blood Flow Metab., 11, S20
  35. Ohno, 1991, Effect of the κ-receptor agonist, U-50,488H, on cerebral ischemia-induced impairment of working memory assessed in rats by a three-panel runway task, Eur. J. Pharmacol., 193, 357, 10.1016/0014-2999(91)90151-F · DOI
  36. Olson, 1979, Effects of an enkephalin analog on complex learning in the Rhesus monkey, Pharmacol. Biochem. Behav., 11, 341, 10.1016/0091-3057(79)90146-1 · DOI
  37. Pan, 1998, μ-Opposing actions of the κ-opioid receptor, Trends Pharmacol. Sci., 19, 94, 10.1016/S0165-6147(98)01169-9 · DOI
  38. Panella, 1984, Lack of clinical benefit from naloxone in a dementia day hospital [letter], Ann. Neurol., 15, 308, 10.1002/ana.410150320 · DOI
  39. Peckys, 1999, Expression of μ, κ, and δ opioid receptor messenger RNA in the human CNS: A 33P in situ hybridization study, Neuroscience, 88, 1093, 10.1016/S0306-4522(98)00251-6 · DOI
  40. Pilapil, 1987, Autoradiographic distribution of multiple classes of opioid receptor binding sites in human forebrain, Brain Res. Bull., 19, 611, 10.1016/0361-9230(87)90080-3 · DOI
  41. Procter, 1988, Topographical distribution of neurochemical changes in Alzheimer’s disease, J. Neurol. Sci., 84, 125, 10.1016/0022-510X(88)90118-9 · DOI
  42. Quirion, 1987, Localization of κ opioid receptor binding sites in human forebrain using [3H]U69593: comparison with [3H]bremazocine, Cell Mol. Neurobiol., 7, 303, 10.1007/BF00711306 · DOI
  43. Reinikainen, 1988, A post-mortem study of noradrenergic, serotonergic and GABAergic neurons in Alzheimer’s disease, J. Neurol. Sci., 84, 101, 10.1016/0022-510X(88)90179-7 · DOI
  44. Reisberg, 1983, Effects of naloxone in senile dementia: a double-blind trial, New Engl. J. Med., 308, 721, 10.1056/NEJM198303243081213 · DOI
  45. Reisine, 1979, Alterations in brain opiate receptors in Parkinson’s disease, Brain Res., 173, 378, 10.1016/0006-8993(79)90642-5 · DOI
  46. Reisine, 1980, Opiate and neuroleptic receptor alterations in human schizophrenic brain tissue, Adv. Biochem. Psychopharmacol., 21, 443
  47. Rinne, 1993, Brain methionine- and leucine-enkephalin receptors in patients with dementia, Neurosci. Lett., 161, 77, 10.1016/0304-3940(93)90144-A · DOI
  48. Risser, 1996, Endogenous opioids in frontal cortex of patients with Down syndrome, Neurosci. Lett., 203, 111, 10.1016/0304-3940(95)12275-3 · DOI
  49. Ritchie, 1996, [3H]Naloxone binding in the human brain: alcoholism and the TaqI A D2 dopamine receptor polymorphism, Brain Res., 718, 193, 10.1016/0006-8993(96)00068-6 · DOI
  50. Rogers, 1985, Quantitative morphology and regional and laminar distributions of senile plaques in Alzheimer’s disease, J. Neurosci., 5, 2801, 10.1523/JNEUROSCI.05-10-02801.1985 · DOI
  51. Royston, 1991, Analysis of laminar distribution of κ opiate receptor in human cortex: comparison between schizophrenia and normal, J. Neurosci. Methods, 36, 145, 10.1016/0165-0270(91)90040-7 · DOI
  52. Schadrack, 1999, Opioid receptors in the human cerebellum: evidence from [11C]diprenorphine PET, mRNA expression and autoradiography, Neuroreport, 10, 619, 10.1097/00001756-199902250-00032 · DOI
  53. Simic, 1997, Volume and number of neurons of the human hippocampal formation in normal aging and Alzheimer’s disease, J. Comp .Neurol., 379, 482, 10.1002/(SICI)1096-9861(19970324)379:4<482::AID-CNE2>3.0.CO;2-Z · DOI · Paper page
  54. Tariot, 1986, Naloxone and Alzheimer’s disease. Cognitive and behavioral effects of a range of doses, Arch. Gen. Psychiatry, 43, 727, 10.1001/archpsyc.1986.01800080013002 · DOI
  55. Ukai, 1993, Dynorphin A-(1-13) attenuates basal forebrain-lesion-induced amnesia in rats, Brain Res., 625, 355, 10.1016/0006-8993(93)91082-4 · DOI
  56. Ukai, 1996, Systemic administration of dynorphin A-(1-13) markedly improves cycloheximide-induced amnesia in mice, Eur. J. Pharmacol., 313, 11, 10.1016/0014-2999(96)00484-0 · DOI
  57. Wall, 2000, U-69,593 microinjection in the infralimbic cortex reduces anxiety and enhances spontaneous alternation memory in mice, Brain Res., 856, 259, 10.1016/S0006-8993(99)01990-3 · DOI
  58. Wegiel, 1999, Cerebellar atrophy in Alzheimer’s disease – clinicopathological correlations, Brain Res., 818, 41, 10.1016/S0006-8993(98)01279-7 · DOI
  59. Yamada, 1997, The expression of mRNA for a κ opioid receptor in the substantia nigra of Parkinson’s disease brain, Brain Res. Mol. Brain Res., 44, 12, 10.1016/S0169-328X(96)00139-8 · DOI
  60. Yew, 1999, Neurotransmitters, peptides, and neural cell adhesion molecules in the cortices of normal elderly humans and Alzheimer patients: a comparison, Exp. Gerontol., 34, 117, 10.1016/S0531-5565(98)00017-5 · DOI
  61. Zager, 1985, Neuropeptides in human memory and learning processes, Neurosurgery, 17, 355, 10.1227/00006123-198508000-00023 · DOI

Cited by

Sorted by citations

Metadata

Authors
Mathieu-Kia, A.-M., Fan, L.-Q., Kreek, M. J., Simon, E. J., & Hiller, J. M.
Affiliations
  • Rockefeller University (US)
  • New York University (US)
Corresponding author
Hiller, Jacob M.
ORCID
Kreek, Mary Jeanne
Venue
Brain Research
Publisher
Elsevier BV
Published
2001-03
Volume
893
Issue
1-2
Pages
121-134
ISSN
0006-8993 (ISSN-L)
DOI
10.1016/s0006-8993(00)03302-3
OpenAlex
W1985833916
Cited by
118
References
3
Citations by year
2026: 2 · 2025: 3 · 2024: 3 · 2023: 4 · 2022: 2 · 2021: 3 · 2020: 5 · 2019: 6 · 2018: 1 · 2017: 6 · 2016: 9 · 2015: 6 · 2014: 6 · 2013: 11 · 2012: 4
FWCI
1.60
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Brain Research (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (1r01da010223-01a1)
  • National Institute on Drug Abuse (DA10223, DA-00017, DA 05130)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
Keywords
Alzheimer's disease, opioid receptors, mu-opioid receptor, delta opioid receptor, kappa opioid receptor, postmortem brain, receptor binding, hippocampus, subiculum, amygdala, putamen, cerebellar cortex, endogenous opioid system, dementia
MeSH terms
Aged, Aged, 80 and over, Aging, Alzheimer Disease, Autoradiography, Brain, Densitometry, Female, Humans, Male, Middle Aged, Tritium, Receptors, Opioid, mu, Receptors, Opioid, delta, Receptors, Opioid, kappa

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review